4-Aminopyridine

• 

  Subject Areas on Research

  • 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). 
  • 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. 
  • 4-Aminopyridine attenuates muscle atrophy after sciatic nerve crush injury in mice. 
  • A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. 
  • Aspartate release from rat hippocampal synaptosomes. 
  • Comment: Is 3,4-DAP a new option in treating MuSK MG? 
  • Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. 
  • Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia. 
  • Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. 
  • In vivo imaging of epileptic activity using 2-NBDG, a fluorescent deoxyglucose analog. 
  • Kv3.1b is a novel component of CNS nodes. 
  • Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. 
  • Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. 
  • Neocortical disynaptic inhibition requires somatodendritic integration in interneurons. 
  • Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia. 
  • The histone lysine demethylase Kdm6b is required for activity-dependent preconditioning of hippocampal neuronal survival. 
  • Transport pathways in rat lingual epithelium.